Medical devices, IVDs, cosmetics and compliance technology.Explore SMEDTEC OS
← Back to Insights
Digital Health ComplianceSamd Regulatory StrategyReal World Evidence Integration

FDA's Dexcom Pilot Signals Real-World Evidence Shift for Digital Health

Sherif Elkhadem
27 July 2026
6 min read
Continuous glucose monitor sensor next to clinical trial documentation on laboratory bench under fluorescent light

The FDA has just named Dexcom as the first manufacturer in its new digital health pilot programme—one that ties device exemptions directly to real-world data collection through Medicare. While the announcement frames this as streamlined access, the implications run deeper: FDA is building infrastructure that rewards continuous evidence generation over static premarket submissions. For software-as-a-medical-device (SaMD) teams and digital health manufacturers, this isn't an isolated experiment. It's a blueprint for how regulators expect evidence to flow across a device's entire lifecycle.

Under the pilot, selected devices will bypass certain premarket requirements in exchange for systematically gathering real-world performance data through Medicare beneficiaries. The trade is explicit: less upfront documentation burden, more post-market accountability. This approach mirrors what we've seen emerging across FDA's SaMD guidance, MHRA's AI sandboxes, and the EU MDR's emphasis on post-market clinical follow-up. What's new here is the operational link to a national payer database—turning reimbursement infrastructure into a regulatory evidence engine.

Why Dexcom—and What It Reveals About FDA's Expectations

Dexcom wasn't chosen arbitrarily. Continuous glucose monitors are high-volume, digitally connected devices with established clinical utility—but they also generate structured, longitudinal data at scale. FDA isn't piloting this pathway with novel AI algorithms or early-stage wearables; it's starting with a device category where real-world evidence infrastructure already exists. That's strategic. The agency is testing whether post-market data collection can reliably substitute for traditional premarket evidentiary packages, and it's doing so where the odds of success are highest.

For manufacturers watching this unfold, the lesson is clear: FDA expects digital health devices to be designed for evidence generation from day one. This isn't about retrofitting post-market surveillance onto a static device; it's about architecting systems that continuously validate performance claims in diverse, real-world populations. The pilot formalises what recent guidance on SaMD and post-market surveillance has been signalling: evidence architecture must precede regulatory submission, not follow it.

Meanwhile, Whoop's hiring of Ami Bhatt—chair of FDA's Digital Health Advisory Committee—as Chief Medical Officer underscores how the industry is responding. Whoop is positioning itself not just as a consumer wearable brand, but as a health technology platform with regulatory credibility baked in. Hiring someone who shapes FDA's digital health policy isn't about navigating clearance faster; it's about aligning product design with emerging regulatory expectations. For startups, the signal is unmistakable: regulatory strategy is no longer a downstream compliance function. It's a core product and commercial competency.

What Real-World Evidence Infrastructure Actually Requires

The Dexcom pilot's structure reveals what FDA considers 'acceptable' real-world evidence: longitudinal, linked to a national dataset (Medicare), and tied to clinical endpoints regulators already trust. This is not passive data collection. It requires interoperability with payer systems, structured data outputs, and predefined analytical frameworks. For most SaMD manufacturers, that's a step-change in technical and operational complexity.

Consider what this means for a startup developing an AI-powered diagnostic or a remote monitoring wearable. To qualify for a pathway like this, you'd need: (1) device outputs that map cleanly to clinical endpoints Medicare tracks, (2) data pipelines capable of feeding structured evidence back to FDA in near-real-time, and (3) quality management systems robust enough to action post-market signals without triggering recalls. Most early-stage teams don't have that infrastructure. But as FDA scales this model beyond Dexcom, it will become table stakes for digital health market access.

This mirrors the shift we've documented around ISO 14155:2026 and post-market surveillance: regulators are no longer satisfied with complaints databases that can't translate signals into clinical action. They want evidence loops that feed directly into risk management and design controls. The Dexcom pilot simply extends that expectation to the premarket phase—rewarding manufacturers who can prove their devices will generate regulatory-grade evidence once deployed.

The Strategic Implications for SaMD and Wearable Manufacturers

If this pilot succeeds, expect FDA to expand it—first to adjacent device categories (other continuous monitors, algorithmically driven diagnostics), then to broader digital health classes. That creates a bifurcated regulatory landscape: manufacturers with evidence infrastructure gain faster, cheaper market access; those relying on traditional premarket pathways face longer timelines and higher evidentiary burdens. For SaMD teams, the competitive advantage shifts from 'can we clear FDA?' to 'can we generate and manage real-world evidence at scale?'

This also intersects directly with cybersecurity and software lifecycle planning. Devices that participate in real-world evidence programmes must maintain data integrity, privacy, and security across distributed deployment environments—often for years post-clearance. That means threat modelling, secure data pipelines, and update mechanisms need to be baked into initial design, not bolted on later. The FDA's evolving cybersecurity guidance already points this direction; the Dexcom pilot makes it operationally non-negotiable.

For regulatory affairs teams, this shift demands new skillsets. Traditional RA professionals excel at assembling static dossiers; what's needed now is continuous evidence curation—knowing which real-world signals matter, how to structure them for regulatory review, and when post-market data triggers a premarket supplement. It's closer to pharmacovigilance than classic device submissions. Teams that can't make that transition will struggle as FDA scales evidence-based pathways.

What This Means for Your Team

If you're developing a digital health device, wearable, or SaMD platform, the Dexcom pilot offers both opportunity and warning. Opportunity: demonstrate your device can generate real-world evidence, and you may access faster, cheaper pathways than traditional 510(k) or PMA routes. Warning: if your product roadmap doesn't include structured evidence generation, you're designing for yesterday's regulatory environment.

Practically, this means: (1) Design data outputs with regulatory endpoints in mind from the start—not just clinical utility, but evidence FDA or notified bodies will recognise. (2) Build interoperability with payer and EHR systems early; if your device can't integrate with Medicare's data infrastructure, you won't qualify for pathways like this. (3) Invest in post-market surveillance architecture before your first submission—FDA increasingly views PMS as a predictor of premarket competence, not an afterthought.

For teams operating across multiple markets, the strategic calculus gets more complex. EU MDR already mandates robust post-market clinical follow-up (PMCF); MHRA is piloting AI sandboxes that reward real-world evidence generation. The Dexcom pilot suggests these requirements are converging globally. Manufacturers who build unified evidence systems—capturing data once, using it for FDA, notified bodies, MHRA, and reimbursement submissions—will scale faster than those managing siloed compliance processes. That's not just regulatory efficiency; it's a core product design decision.

Key Takeaways

  • FDA's Dexcom pilot links device exemptions to Medicare-based real-world evidence collection, rewarding continuous post-market data generation over static premarket submissions.
  • Manufacturers must design for evidence infrastructure from day one—interoperability with payer systems, structured data outputs, and regulatory-grade analytics are now table stakes for digital health market access.
  • Whoop's hire of FDA Digital Health Advisory Committee chair signals industry recognition that regulatory strategy is a core product and commercial competency, not a downstream compliance function.
  • This pathway will likely expand beyond CGMs to other SaMD categories, creating competitive advantage for teams that can manage real-world evidence at scale and disadvantaging those reliant on traditional premarket-only approaches.
  • Cross-market teams should build unified evidence systems that serve FDA, EU MDR PMCF, and MHRA requirements simultaneously—fragmented compliance processes won't scale as global regulators converge on evidence-based pathways.

The Dexcom pilot isn't just about streamlining one company's clearance path. It's FDA testing the operational infrastructure for a post-market evidence economy—one where devices earn continued market access by proving real-world performance, not just premarket safety. For digital health and SaMD manufacturers, that shift is already underway. The question isn't whether your evidence systems are ready; it's whether your product design, data architecture, and regulatory operations can sustain the model FDA is building. Teams that answer 'yes' will lead the next generation of digital health approvals. Those that can't will find themselves designing for a regulatory framework that no longer exists.

Sources cited in this digest

Related Articles

Quality Management

Expedited SaMD Change Control and Medical Device Fraud Signals

Greenlight Guru's expedited change control guidance arrives as MHRA secures fraud convictions over falsely certified devices. For SaMD teams, these stories reveal where speed and integrity must coexist.

7 October 2026
Regulatory Strategy For Medtech

FDA TEMPO and IVD Clearance Reveal Expedited Pathway Mechanics

FDA adds two behavioral health SaMD firms to TEMPO while clearing Roche and Abbott IVD innovations. For RA teams, these approvals reveal the evidence architecture and pathway logic now reshaping review timelines.

26 August 2026
Ai Compliance Strategy Medtech

AI compliance for SaMD: where teams fail before the first audit

FDA seeks generative AI input while SaMD teams ship broken compliance architectures. The gap isn't technical knowledge, it's evidence structure.

21 August 2026

Need Regulatory Guidance?

Get expert help with your medical device regulatory strategy. From EU MDR compliance to FDA submissions, we're here to help.

Get Started →More Articles